A carregar...
BET inhibition overcomes receptor tyrosine kinase-mediated cetuximab resistance in HNSCC
Cetuximab, the FDA-approved anti-EGFR antibody for head and neck squamous cell carcinoma (HNSCC), has displayed limited efficacy due to the emergence of intrinsic and acquired resistance. We and others have demonstrated that cetuximab resistance in HNSCC is driven by alternative receptor tyrosine ki...
Na minha lista:
| Publicado no: | Cancer Res |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6072571/ https://ncbi.nlm.nih.gov/pubmed/29792310 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-18-0459 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|